Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Price Performance

Shares of NASDAQ:NERV opened at $2.68 on Wednesday. The company’s 50-day moving average price is $2.21 and its two-hundred day moving average price is $2.54. Minerva Neurosciences has a one year low of $2.03 and a one year high of $13.49. The stock has a market capitalization of $18.73 million, a PE ratio of -6.09 and a beta of 0.11.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.